



BILLING CODE: 3710-08

DEPARTMENT OF DEFENSE

Department of the Army

**Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing
of an Invention Concerning Contact Pathway and Tissue Kallikrein Inhibitors can
Prevent/Reduce Leakage Caused by Hantavirus**

AGENCY: Department of the Army, DoD.

ACTION: Notice.

SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/851,573, entitled "Contact Pathway and Tissue Kallikrein Inhibitors can Prevent/Reduce Leakage Caused by Hantavirus," filed on March 15, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619-6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The invention relates to treatment of vascular leakage symptoms infected with the Hantavirus using drugs that are already FDA approved.

Brenda S. Bowen
Army Federal Register Liaison Officer

[FR Doc. 2014-00285 Filed 01/10/2014 at 8:45 am; Publication Date: 01/13/2014]